Patent ID: 8343457

Claim:
A method of identifying a patient as prodromal to a disease associated with amyloid deposition, comprising (A) administering to the patient in need thereof an effective amount of a radiolabeled compound of formula (II): or a pharmaceutically acceptable salt, of the compound, wherein: R 1 is hydrogen, —OH, —NO 2 , —CN, —COOR, —OCH 2 OR, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy or halo; R is C 1 -C 6 alkyl; R 2 is hydrogen or halo; R 3 is hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl; and R 4 is hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, wherein the alkyl, alkenyl or alkynyl comprises a radioactive carbon or is substituted with a radioactive halo when R 2 is hydrogen or a non-radioactive halo, provided that, when R 1 is hydrogen or —OH, R 2 is hydrogen and R 4 is — 11 CH 3 , then R 3 is C 2 -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, and further provided that, when R 1 is hydrogen, R 2 hydrogen and R 4 is —(CH 2 ) 3 18 F, then R 3 is C 2 -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, (B) imaging said patient, then (C) administering to said patient in need thereof at least one anti-amyloid agent, (D) subsequently administering to said patient in need thereof an effective amount of a compound of formula (II), (E) imaging said patient, and (F) comparing levels of amyloid deposition in said patient before treatment with said at least one anti-amyloid agent to levels of amyloid deposition in said patient after treatment with said at least one anti-amyloid agent.